Combinatorial chloride and calcium channelopathy in myotonic dystrophy.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
pubmed:
3
7
2023
medline:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Myotonic dystrophy type 1 (DM1) involves misregulated alternative splicing for specific genes. We used exon or nucleotide deletion to mimic altered splicing of genes central to muscle excitation-contraction coupling processes in mice. Mice with forced-skipping of exon 29 in Ca
Identifiants
pubmed: 37398406
doi: 10.1101/2023.05.29.542752
pmc: PMC10312834
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR079424
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM135134
Pays : United States
Organisme : NIDCR NIH HHS
ID : T90 DE021985
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002001
Pays : United States
Déclaration de conflit d'intérêts
Competing interests: J.D.L., L.A.C. and C.A.T. are co-inventors of the technology presented in this study. PCT/US22/79593 Claims Priority to U.S. Provisional Patent Application Nos. 63/277,816 & 63/374,378, Title: TREATMENT OF MYOTONIC DISORDERS. Inventors - University of Rochester School of Medicine and Dentistry – Inventors - J.D.L., L.A.C. and C.A.T. pertains to the use of verapamil to treat myotonic disorders in this study.